{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:30:14Z","timestamp":1793637014043,"version":"4.5.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.neo.2026.101383","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T09:50:54Z","timestamp":1792230654000},"page":"101383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Antigen persistence after antibody-drug conjugates in urothelial carcinoma: implications for CAR-cell target selection"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4973-0077","authenticated-orcid":false,"given":"Jiayi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoqiang","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.neo.2026.101383_bib0001","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.neo.2026.101383_bib0002","first-page":"1245","article-title":"Targeting bladder cancer using activated T cells armed with bispecific antibodies","volume":"39","author":"Ma","year":"2018","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.neo.2026.101383_bib0011","doi-asserted-by":"crossref","first-page":"8215","DOI":"10.1038\/s41467-025-62710-0","article-title":"Modulating the PPAR\u03b3 pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer","volume":"16","author":"Chang","year":"2025","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.neo.2026.101383_bib0020","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3390\/cancers11030394","article-title":"Acquired resistance to antibody-drug conjugates","volume":"11","author":"Collins","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.neo.2026.101383_bib0021","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"issue":"2","key":"10.1016\/j.neo.2026.101383_bib0022","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1158\/0008-5472.CAN-25-0024","article-title":"Targeting sialylation enhances the therapeutic efficacy of the nectin-4-targeted antibody-drug conjugate enfortumab vedotin in bladder cancer","volume":"86","author":"Wu","year":"2026","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.neo.2026.101383_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2026.04.010","article-title":"Endocytic evasion confers resistance to antibody-drug conjugates therapy in cancer","volume":"44","author":"Wang","year":"2026","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.neo.2026.101383_bib0024","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/1878-0261.70187","article-title":"Therapeutic strategies for MMAE-resistant bladder cancer through DPP4 inhibition","volume":"20","author":"Li","year":"2026","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.neo.2026.101383_bib0025","doi-asserted-by":"crossref","DOI":"10.1002\/bco2.488","article-title":"Predictive role of ABC transporters in the efficacy of enfortumab vedotin for urothelial carcinoma","volume":"6","author":"Kijima","year":"2025","journal-title":"BJUI Compass"},{"issue":"2","key":"10.1016\/j.neo.2026.101383_bib0026","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/iju5.12696","article-title":"Increased expression of ATP-binding cassette transporters in enfortumab vedotin-resistant urothelial cancer","volume":"7","author":"Kotono","year":"2024","journal-title":"IJU Case Rep."},{"issue":"3","key":"10.1016\/j.neo.2026.101383_bib0029","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.neo.2026.101383_bib0031","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.neo.2026.101383_bib0003","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","article-title":"Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin","volume":"27","author":"Chu","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.neo.2026.101383_bib0004","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Kl\u00fcmper","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.neo.2026.101383_bib0005","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.urolonc.2026.111095","article-title":"Concordance and prognostic value of antibody drug conjugate and checkpoint inhibition targets in matched bladder cancer specimens from transurethral resection of the bladder, radical cystectomy and lymphadenectomy","volume":"44","author":"Uysal","year":"2026","journal-title":"Urol Oncol."},{"key":"10.1016\/j.neo.2026.101383_bib0006","doi-asserted-by":"crossref","DOI":"10.1177\/17588359261463147","article-title":"Site-specific differences in Nectin-4 expression and associated immune contexture in advanced urothelial carcinoma: implications for Nectin-4-targeted ADCs","volume":"18","author":"Hsueh","year":"2026","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"7","key":"10.1016\/j.neo.2026.101383_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100753","article-title":"Spatial Expression of HER2, NECTIN4, and TROP-2 in muscle-invasive bladder cancer and metastases: implications for pathological and clinical management","volume":"38","author":"Dernbach","year":"2025","journal-title":"Mod. Pathol."},{"issue":"6","key":"10.1016\/j.neo.2026.101383_bib0008","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.clgc.2023.05.014","article-title":"Metastatic bladder cancer expression and subcellular localization of nectin-4 and trop-2 in variant histology: a rapid autopsy study","volume":"21","author":"Ghali","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.neo.2026.101383_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.858865","article-title":"Head-to-head comparison of the expression differences of NECTIN-4, TROP-2, and HER2 in urothelial carcinoma and its histologic variants","volume":"12","author":"Fan","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.neo.2026.101383_bib0010","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1038\/s41467-025-59888-8","article-title":"Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression","volume":"16","author":"Yang","year":"2025","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.neo.2026.101383_bib0012","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/RLU.0000000000006528","article-title":"[ 68 Ga]Ga-NECT-224 PET\/CT shows increasing nectin-4 expression in progressive urothelial carcinoma under adc-therapy with enfortumab-vedotin","volume":"51","author":"Hober\u00fcck","year":"2026","journal-title":"Clin. Nucl. Med."},{"issue":"2","key":"10.1016\/j.neo.2026.101383_bib0013","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/curroncol33020103","article-title":"Predictors of response and mechanisms of resistance to antibody drug conjugates in urothelial carcinoma","volume":"33","author":"Huang","year":"2026","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.neo.2026.101383_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2026.103173","article-title":"Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody-drug conjugates","volume":"148","author":"Wafa","year":"2026","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.neo.2026.101383_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2026.105275","article-title":"Progress and challenges in CAR-T cell therapy for bladder cancer","volume":"222","author":"Zhao","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.neo.2026.101383_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2026.105208","article-title":"Natural killer and CAR-NK cell therapies in urological cancers: Progress, mechanistic lessons from CAR-T, and future directions","volume":"221","author":"Zhou","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"20","key":"10.1016\/j.neo.2026.101383_bib0017","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer","volume":"42","author":"Kl\u00fcmper","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2026.101383_bib0018","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-26-0093","article-title":"Integrating NECTIN4 amplification with membranous nectin-4 expression to develop a scoring system for predicting enfortumab vedotin response in urothelial carcinoma","author":"Kl\u00fcmper","year":"2026","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.neo.2026.101383_bib0019","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/jha2.816","article-title":"In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine","volume":"5","author":"Caimi","year":"2024","journal-title":"EJHaem"},{"issue":"1","key":"10.1016\/j.neo.2026.101383_bib0027","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.annonc.2023.09.3114","article-title":"The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma","volume":"35","author":"McGregor","year":"2024","journal-title":"Ann. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.neo.2026.101383_bib0028","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2026.44.16_suppl.4508","article-title":"Initial results from NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4, in participants with advanced or metastatic urothelial carcinoma","volume":"44","author":"Iyer","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2026.101383_bib0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41467-017-00147-w","article-title":"Evasion of immunosurveillance by genomic alterations of PPAR\u03b3\/RXR\u03b1 in bladder cancer","volume":"8","author":"Korpal","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.neo.2026.101383_bib0032","doi-asserted-by":"crossref","DOI":"10.1002\/iju5.70122","article-title":"Salvage surgery for primary renal pelvic urothelial carcinoma after enfortumab vedotin: a case of durable remission with nectin-4 loss","volume":"9","author":"Wakamiya","year":"2026","journal-title":"IJU Case Rep."},{"issue":"5","key":"10.1016\/j.neo.2026.101383_bib0033","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the antigen density requirement for CAR T-cell Activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.neo.2026.101383_bib0034","doi-asserted-by":"crossref","first-page":"7196","DOI":"10.1038\/s41467-025-61427-4","article-title":"Functional avidity of anti-B7H3 CAR-T constructs predicts antigen density thresholds for triggering effector function","volume":"16","author":"Barisa","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.neo.2026.101383_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2021.12.005","article-title":"GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity","volume":"40","author":"Heitzeneder","year":"2022","journal-title":"Cancer Cell"},{"issue":"17","key":"10.1016\/j.neo.2026.101383_bib0036","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1158\/1078-0432.CCR-23-0609","article-title":"First-in-human study of the radioligand 68ga-n188 targeting nectin-4 for PET\/CT imaging of advanced urothelial carcinoma","volume":"29","author":"Duan","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.neo.2026.101383_bib0037","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/bju.16901","article-title":"Staging metastatic urothelial cancer with Nectin-4 imaging using Gallium-68-N188 PET\/CT","volume":"137","author":"Miederer","year":"2026","journal-title":"BJU Int."},{"issue":"1","key":"10.1016\/j.neo.2026.101383_bib0041","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s00280-025-04783-8","article-title":"Clinical relevance of Nectin-4 downregulation and biological changes caused by cytotoxic chemotherapy in bladder cancer","volume":"95","author":"Miyake","year":"2025","journal-title":"Cancer Chemother Pharmacol."},{"issue":"6","key":"10.1016\/j.neo.2026.101383_bib0042","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.euo.2021.11.005","article-title":"TROP2 expression across molecular subtypes of urothelial carcinoma and enfortumab vedotin-resistant cells","volume":"5","author":"Chou","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.neo.2026.101383_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218254","article-title":"ABCG2-mediated SN-38 efflux drives resistance to Sacituzumab govitecan in urothelial carcinoma","volume":"640","author":"Prantl","year":"2026","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.neo.2026.101383_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105305","article-title":"Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma","volume":"10","author":"Sternschuss","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.neo.2026.101383_bib0045","article-title":"Testing and interpretation of human epidermal growth factor receptor 2 protein expression and ERBB2 gene amplification in advanced urothelial carcinoma","volume":"9","author":"Koshkin","year":"2025","journal-title":"JCO Precis Oncol."},{"issue":"1","key":"10.1016\/j.neo.2026.101383_bib0046","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s41467-025-67643-2","article-title":"Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer","volume":"17","author":"Chen","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neo.2026.101383_bib0047","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2026.1887794","article-title":"The expression landscape and heterogeneity of nectin-4, HER2, and Trop-2 in urothelial carcinoma: clinicopathological correlations and implications for ADC-guided precision therapy","volume":"16","author":"Qin","year":"2026","journal-title":"Front. Oncol."},{"key":"10.1016\/j.neo.2026.101383_bib0038","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41467-020-20493-6","article-title":"Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer","volume":"12","author":"Vandekerkhove","year":"2021","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.neo.2026.101383_bib0039","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/BLC-160069","article-title":"Clinical significance of early changes in circulating tumor cells from patients receiving first-line cisplatin-based chemotherapy for metastatic urothelial carcinoma","volume":"2","author":"Fina","year":"2016","journal-title":"Bladder Cancer"},{"issue":"16_suppl","key":"10.1016\/j.neo.2026.101383_bib0040","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1200\/JCO.2026.44.16_suppl.4588","article-title":"Use of NECTIN4 expression inferred from circulating chromatin to predict response and survival to enfortumab vedotin (EV) in metastatic urothelial carcinoma","volume":"44","author":"Nawfal","year":"2026","journal-title":"J. Clin. Oncol.."},{"issue":"2","key":"10.1016\/j.neo.2026.101383_bib0048","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1248","article-title":"Patient-derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR-T cells in vitro","volume":"10","author":"Yu","year":"2021","journal-title":"Clin. Transl. Immunol."},{"issue":"40","key":"10.1016\/j.neo.2026.101383_bib0049","article-title":"Novel CAR-T cells specifically targeting SIA-CIgG demonstrate effective antitumor efficacy in bladder cancer","volume":"11","author":"Ding","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"issue":"7","key":"10.1016\/j.neo.2026.101383_bib0050","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20250699","article-title":"Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models","volume":"223","author":"Abrahimi","year":"2026","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.neo.2026.101383_bib0051","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s10147-025-02822-1","article-title":"Factors associated with primary resistance to enfortumab vedotin in previously treated patients with metastatic urothelial carcinoma: a multicenter retrospective study","volume":"30","author":"Ikarashi","year":"2025","journal-title":"Int. J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.neo.2026.101383_bib0052","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.neo.2026.101383_bib0053","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1490911","article-title":"Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies","volume":"15","author":"Nolan-Stevaux","year":"2024","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.neo.2026.101383_bib0054","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/cells14050320","article-title":"Strategies to overcome antigen heterogeneity in CAR-T cell therapy","volume":"14","author":"Zhang","year":"2025","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.neo.2026.101383_bib0055","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008566","article-title":"Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity","volume":"12","author":"Shabaneh","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"6534","key":"10.1016\/j.neo.2026.101383_bib0056","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1126\/science.abc1855","article-title":"T cell circuits that sense antigen density with an ultrasensitive threshold","volume":"371","author":"Hernandez-Lopez","year":"2021","journal-title":"Science"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558626001156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558626001156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:18:14Z","timestamp":1793636294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558626001156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":56,"alternative-id":["S1476558626001156"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2026.101383","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antigen persistence after antibody-drug conjugates in urothelial carcinoma: implications for CAR-cell target selection","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2026.101383","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101383"}}